Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction
The Journal of Cardiovascular Aging · 2022
DOI: 10.20517/jca.2021.21 ↗At a glance
Journal article in The Journal of Cardiovascular Aging, 2022. Written by Michael A Bellio and 8 co-authors. Institution: Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Cited 11 times so far (Crossref). The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, Marcus Foundation.
Abstract (original language)
INTRODUCTION: Cardiovascular disease and myocardial infarction are leading causes of morbidity and mortality in aged populations. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) are under evaluation as a therapeutic option for the treatment of myocardial infarction. AIM: This study aimed to develop a large-scale manufacturing procedure to harvest clinical-grade EVs required for the translation of EVs to the clinic. METHODS AND RESULTS: We compared the efficiency of large scale MSC-derived EV production and characterized EV miRNA cargo using the Quantum bioreactor with either fetal bovine serum or human platelet lysate (PLT)-containing expansion media. We tested the potency of the EV products in a murine model of acute myocardial infarction. Our results demonstrate an advantage of the Quantum bioreactor as a large-scale platform for EV production using PLT media; however, both media produced EVs with similar effects in vivo. The systemic delivery of EV products improved cardiac function following myocardial infarctions as indicated by a significant improvement in ejection fraction as well as parameters of cardiac performance, afterload, contractility and lusitropy. CONCLUSION: These findings have important implications for scale-up strategies of EVs and will facilitate clinical trials for their clinical evaluation.
Subjects
Author keywords
Authors and institutions
- Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Pediatrics, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Division of Neonatology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Funding
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- Marcus Foundation
Cite
APA
Bellio, M. A., Kanashiro-Takeuchi, R. M., Takeuchi, L., Kulandavelu, S., Lee, Y. S., Balkan, W., Young, K. C., Hare, J. M., & Khan, A. (2022). Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction. The Journal of Cardiovascular Aging. https://doi.org/10.20517/jca.2021.21
Vancouver
Bellio MA, Kanashiro-Takeuchi RM, Takeuchi L, Kulandavelu S, Lee YS, Balkan W, et al. Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction. The Journal of Cardiovascular Aging. 2022. doi:10.20517/jca.2021.21
BibTeX
@article{Bellio2022,
author = {Bellio, Michael A and Kanashiro-Takeuchi, Rosemeire M and Takeuchi, Lauro and Kulandavelu, Shathiyah and Lee, Yee-Shuan and Balkan, Wayne and Young, Karen C and Hare, Joshua M and Khan, Aisha},
title = {Systemic delivery of large-scale manufactured Wharton’s Jelly mesenchymal stem cell-derived extracellular vesicles improves cardiac function after myocardial infarction},
journal = {The Journal of Cardiovascular Aging},
year = {2022},
doi = {10.20517/jca.2021.21}
}
EUVIMED